5:31 PM
Oct 08, 2013
 |  BC Extra  |  Clinical News

GSK planning EMA submission for malaria vaccine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said next year it plans to submit a regulatory application to EMA for its RTS,S vaccine to prevent malaria infection in infants and children. The news came after the pharma published additional data from a Phase III trial showing three doses of the vaccine reduced the incidence of clinical malaria over an 18-month period following vaccination...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >